title: Highlights of the 2014 International AIDS Conference: update from down under.
abstract: The 20th International AIDS Conference held in Melbourne, Australia, from July 20 through July 25, 2014, provided much new data on nucleoside analogue reverse transcriptase inhibitor-sparing antiretroviral therapy, potential consequences of switching suppressive antiretroviral regimen, antiretroviral treatment with integrase strand transfer inhibitors, effects of antiretroviral therapy on HIV-associated neurocognitive impairment, and hepatitis C virus (HCV) treatment in HIV/HCV-coinfected individuals. This article summarizes an IAS-USA continuing education webinar presented by Paul A. Volberding, MD, in August 2014, in which he focused on a few select highlights from the Conference.
authors.affiliation: University of California San Francisco, San Francisco, CA, USA.
authors.forename: Paul A
authors.initials: PA
authors.lastname: Volberding
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000150:complications / Q000188:drug therapy*; D023241:Antiretroviral Therapy, Highly Active / Q000379:methods*; D000998:Antiviral Agents / Q000627:therapeutic use*; D001315:Australia; D035843:Biomedical Research / Q000639:trends; D014943:Global Health; D019698:Hepatitis C, Chronic / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D016019:Survival Analysis; D016896:Treatment Outcome; D014481:United States
chemical_list: D000998:Antiviral Agents